Eiger BioPharmaceuticals, Inc. (EIGRQ)

Eiger BioPharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	15.77	15.77	13.48	12.14	0	0
Revenue Growth (YoY)	16.98%	16.98%	11.05%	-	-	-
Cost of Revenue	0.02	0.02	1.84	0.75	0	0
Gross Profit	15.75	15.75	11.65	11.4	0	0
Selling, General & Admin	25.2	25.2	29.11	23.9	20.56	17.11
Research & Development	62.33	62.33	75.28	64.44	41.59	51.79
Operating Expenses	87.54	87.54	104.39	88.34	62.15	68.9
Operating Income	-71.79	-71.79	-92.74	-76.94	-62.15	-68.9
Interest Expense / Income	5.47	5.47	4.13	3.56	3.59	3.41
Other Expense / Income	-2.3	-2.3	-0.12	-46.65	-0.69	-2.06
Pretax Income	-74.96	-74.96	-96.75	-33.85	-65.05	-70.25
Income Tax	0.01	0.01	0.02	0.06	0	0
Net Income	-74.96	-74.96	-96.78	-33.92	-65.05	-70.25
Shares Outstanding (Basic)	1	1	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1	1	1
Shares Change	6.39%	6.39%	22.64%	20.61%	23.51%	67.12%
EPS (Basic)	-50.78	-50.78	-69.74	-30.00	-69.30	-92.40
EPS (Diluted)	-50.78	-50.78	-69.74	-30.00	-69.30	-92.40
Free Cash Flow	-74.78	-74.78	-83.35	-71.29	-63.44	-64.09
Free Cash Flow Per Share	-50.66	-50.66	-60.07	-63.00	-67.63	-84.38
Gross Margin	99.85%	99.85%	86.38%	93.86%	-	-
Operating Margin	-455.12%	-455.12%	-687.78%	-633.66%	-	-
Profit Margin	-475.26%	-475.26%	-717.71%	-279.34%	-	-
Free Cash Flow Margin	-474.11%	-474.11%	-618.14%	-587.10%	-	-
EBITDA	-68.74	-68.74	-91.78	-29.5	-60.81	-66.36
EBITDA Margin	-435.81%	-435.81%	-680.65%	-242.92%	-	-
Depreciation & Amortization	0.75	0.75	0.84	0.8	0.65	0.49
EBIT	-69.49	-69.49	-92.62	-30.29	-61.46	-66.85
EBIT Margin	-440.57%	-440.57%	-686.90%	-249.50%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).